The impact of viral evolution and frequency of variant epitopes on primary and memory human immunodeficiency virus type 1-specific CD8+ T cell responses
| dc.contributor.author | Melhem, Nada Mohamad | |
| dc.contributor.author | Smith, Kellie N. | |
| dc.contributor.author | Huang, Xiaoli | |
| dc.contributor.author | Colleton, Bonnie A. | |
| dc.contributor.author | Jiang, Weimin | |
| dc.contributor.author | Mailliard, Robbie B. | |
| dc.contributor.author | Mullins, James I. | |
| dc.contributor.author | Rinaldo, Charles R. | |
| dc.contributor.department | Medical Laboratory Sciences Program (MLSP) | |
| dc.contributor.faculty | Faculty of Health Sciences (FHS) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T11:36:23Z | |
| dc.date.available | 2025-01-24T11:36:23Z | |
| dc.date.issued | 2014 | |
| dc.description.abstract | It is unclear if HIV-1 variants lose the ability to prime naïve CD8+ cytotoxic T lymphocytes (CTL) during progressive, untreated infection. We conducted a comprehensive longitudinal analysis of viral evolution and its impact on primary and memory CD8+ T cell responses pre-seroconversion (SC), post-SC, and during combination antiretroviral therapy (cART). Memory T cell responses targeting autologous virus variants reached a nadir by 8 years post-SC with development of AIDS, followed by a transient enhancement of anti-HIV-1 CTL responses upon initiation of cART. We show broad and high magnitude primary T cell responses to late variants in pre-SC T cells, comparable to primary anti-HIV-1 responses induced in T cells from uninfected persons. Despite evolutionary changes, CD8+ T cells could still be primed to HIV-1 variants. Hence, vaccination against late, mutated epitopes could be successful in enhancing primary reactivity of T cells for control of the residual reservoir of HIV-1 during cART. © 2013. | |
| dc.identifier.doi | https://doi.org/10.1016/j.virol.2013.10.015 | |
| dc.identifier.eid | 2-s2.0-84890810921 | |
| dc.identifier.pmid | 24503065 | |
| dc.identifier.uri | http://hdl.handle.net/10938/28588 | |
| dc.language.iso | en | |
| dc.relation.ispartof | Virology | |
| dc.source | Scopus | |
| dc.subject | Autologous viral variants | |
| dc.subject | Cart | |
| dc.subject | Hiv-1 | |
| dc.subject | Memory t cell responses | |
| dc.subject | Primary t cell responses | |
| dc.subject | Adult | |
| dc.subject | Anti-hiv agents | |
| dc.subject | Cd8-positive t-lymphocytes | |
| dc.subject | Cohort studies | |
| dc.subject | Epitopes, t-lymphocyte | |
| dc.subject | Evolution, molecular | |
| dc.subject | Histocompatibility antigens class i | |
| dc.subject | Hiv infections | |
| dc.subject | Humans | |
| dc.subject | Male | |
| dc.subject | T-lymphocytes | |
| dc.subject | Viral proteins | |
| dc.subject | Abacavir | |
| dc.subject | Antiretrovirus agent | |
| dc.subject | Cd8 antigen | |
| dc.subject | Efavirenz | |
| dc.subject | Efavirenz plus emtricitabine plus tenofovir disoproxil | |
| dc.subject | Epitope | |
| dc.subject | Lamivudine | |
| dc.subject | Nelfinavir | |
| dc.subject | Saquinavir | |
| dc.subject | Zidovudine | |
| dc.subject | Acquired immune deficiency syndrome | |
| dc.subject | Antigen specificity | |
| dc.subject | Article | |
| dc.subject | Cd8+ t lymphocyte | |
| dc.subject | Genetic conservation | |
| dc.subject | Human | |
| dc.subject | Human cell | |
| dc.subject | Human immunodeficiency virus 1 | |
| dc.subject | Human immunodeficiency virus 1 infection | |
| dc.subject | Immunoreactivity | |
| dc.subject | Memory t lymphocyte | |
| dc.subject | Nonhuman | |
| dc.subject | Priority journal | |
| dc.subject | Seroconversion | |
| dc.title | The impact of viral evolution and frequency of variant epitopes on primary and memory human immunodeficiency virus type 1-specific CD8+ T cell responses | |
| dc.type | Article |
Files
Original bundle
1 - 1 of 1